LFA-1 regulated by IL-2/STAT5 pathway boosts antitumor function of intratumoral CD8+ T cells for improving anti-PD-1 antibody therapy
Anti-PD-1 antibody therapy has achieved success in tumor treatment; however, the duration of its clinical benefits are typically short. The functional state of intratumoral CD8+ T cells substantially affects the efficacy of anti-PD-1 antibody therapy. Understanding how intratumoral CD8+ T cells chan...
Saved in:
| Main Authors: | Jiqi Shan, Wei Jing, Yu Ping, Chunyi Shen, Dong Han, Fengsen Liu, Yaqing Liu, Congcong Li, Yi Zhang |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2024-12-01
|
| Series: | OncoImmunology |
| Subjects: | |
| Online Access: | https://www.tandfonline.com/doi/10.1080/2162402X.2023.2293511 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Tumor cells escape immunosurveillance by hampering LFA-1
by: Shishir Upadhyay, et al.
Published: (2025-01-01) -
Luteolin prevents fMLP-induced neutrophils adhesion via suppression of LFA-1 and phosphodiesterase 4 activity
by: Dai-xun JIANG, et al.
Published: (2015-01-01) -
The comparison of efficacy and safety between cadonilimab (PD-1/CTLA-4) and anti-PD-1 inhibitors in patients with recurrent or metastatic cervical cancer: a retrospective real-world study
by: Baoyue Pan, et al.
Published: (2025-06-01) -
Association of Hepatitis-B virus infection status with survival and treatment response in non-small cell lung cancer patients on anti‐pd‐1/pd-l1 therapy
by: Eda Alp, et al.
Published: (2024-12-01) -
Comparison of treatment outcome between first‐line combination immunotherapy (anti‐PD‐L1 or anti‐PD1) with or without chemotherapy and chemotherapy alone in advanced non‐small cell lung cancer patients in tertiary care hospital
by: Danainut Naratornsirakul, et al.
Published: (2024-07-01)